Evidence map›Paper›PMID 41665021›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Amyloid β Instigates Cardiac Neurotrophic Signaling Impairment, Driving Alzheimer's Associated Heart Disease.

Andrea Elia, Rebecca Parodi-Rullan, Rafael Vazquez-Torres, Ashley Carey, Huaqing Zhao, Sabzali Javadov, Silvia Fossati

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Andrea EliaAlzheimer's Center at Temple (ACT), Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-3220-7893
Rebecca Parodi-RullanAlzheimer's Center at Temple (ACT), Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Rafael Vazquez-TorresAlzheimer's Center at Temple (ACT), Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Ashley CareyAlzheimer's Center at Temple (ACT), Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Huaqing ZhaoCenter for Biostatistics and Epidemiology, Department of Biomedical Education and Data Science, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.
Sabzali JavadovDepartment of Physiology, University of Puerto Rico School of Medicine, San Juan, USA.
Silvia FossatiAlzheimer's Center at Temple (ACT), Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-2047-222X

Funding

Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factorsR01NS104127 · NINDS · TEMPLE UNIV OF THE COMMONWEALTH · PI FOSSATI, SILVIA · 2018 to 2022
$3.0M
Targeting carbonic anhydrases in Alzheimer's diseaseR01AG062572 · NIA · TEMPLE UNIV OF THE COMMONWEALTH · PI FOSSATI, SILVIA · 2019 to 2023
$2.3M
Alzheimer's Association AARG-20-685663American Heart Association 24POST1240115National Institute of General Medical Sciences (NIGMS) SC1GM128210NIA NIH HHS R01 AG062572NIH National Institute of Neurological Disorders and Stroke R01NS104127NIH National Institute on Aging R01AG062572NINDS NIH HHS R01 NS104127Pennsylvania Department of Health PACure;CollaborativeResearchonAlzheimer'sDisease
6 · The paper itself

Abstract

While a link between cardiovascular risk factors and increased Alzheimer's disease (AD) risk has been reported, it remains unclear whether AD pathology has a direct effect on cardiac function and myocardial innervation. AD and amyloidosis are known to impair neuronal function and affect brain neurotrophic factors (NGF and BDNF) expression. Amyloid aggregates and neuro-signaling impairments may also expose AD patients to peripheral nervous system deficits, promoting cardiac disorders. Here, we provide novel understanding of cardiac physiological impairment, amyloid pathology, neurotrophic factors loss, and impoverishment of cardiac neuronal fibers in Tg2576-AD mice hearts, human cardiomyocytes in culture, and human AD post-mortem left ventricular (LV) heart tissue. We reveal that Tg2576 animals exhibit increased myocardial fibrosis, amyloid β (Aβ) deposition, and brain/heart-axis neurotrophic deficiencies, resulting in myocardial denervation and cardiac dysfunction. Aβ oligomers challenge reduces BDNF expression in both human immortalized and iPSC-derived cardiomyocytes, by disrupting TrkB/CREB signaling. Analysis of human LV AD post-mortem tissue confirms cell and animal results. Our findings reveal potential pathways by which Aβ pathology may disrupt cardiac neurotrophic signaling and physiology, identifying a possible link between AD and heart degeneration.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesHeart DiseasesAnimalsBrain-Derived Neurotrophic FactorDisease Models, AnimalHumansMaleMiceMice, TransgenicMyocardiumMyocytes, CardiacSignal TransductionAmyloid beta-PeptidesBrain-Derived Neurotrophic FactorAlzheimer's diseasebrain‐heart axis neuro‐signaling pathwaycardiac dysfunctionhuman iPSC‐derived cardiomyocyteshuman post‐mortem heart

Identifiers

PMID41665021
PMCPMC13067842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.